Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Amylin, Lilly Partnership Tested By Lilly GLP-1 Project

  • News

Executive Summary

Amylin expects to discuss changes to its partnership agreement with Lilly if Lilly's internal GLP-1 antidiabetic compound LY2189265 continues to progress in the clinic

You may also be interested in...



Mystery Suitor Thwarts Bristol’s ImClone Takeover, Or So Icahn Says

Intrigue surrounding Bristol-Myers Squibb's takeover attempt of its Erbitux (cetuximab) marketing partner ImClone reached new heights with the announcement Sept. 10 that a third-party mystery suitor has stepped in with a white knight bid

The Next Bristol/ImClone? “Standstill” Provisions Complicate Other Deals

Roche and Bristol-Myers Squibb have everyone wondering who will be the next company to buy out its biotech partner

Byetta Scripts, LAR Progress Unaffected By Safety Scare, Amylin Says

FDA's review of a new monotherapy indication for Amylin's type 2 diabetes agent Byetta (exenatide) may provide the opportunity for updating the labeling to reflect a stronger warning on pancreatitis

Table

View full table

Related Content

Pink Sheet
In Vivo
Tags:
Latest Headlines

Patent Office Issues Proposed Rule For Rarely Successful Director Review Requests

Medicare Spending Forecast For Leqembi Reflects CMS Angst About Alzheimer’s Drug Costs

US FDA Drugs Center Launches Clinical Trial Innovation Hub With Demonstration Projects

EMA Releases Guidance On How & When Its RWE Generation Service Can Be Used

See All
UsernamePublicRestriction

Register

PS050138

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By